615 related articles for article (PubMed ID: 10637244)
1. Rapid hematopoietic recovery after coinfusion of autologous-blood stem cells and culture-expanded marrow mesenchymal stem cells in advanced breast cancer patients receiving high-dose chemotherapy.
Koç ON; Gerson SL; Cooper BW; Dyhouse SM; Haynesworth SE; Caplan AI; Lazarus HM
J Clin Oncol; 2000 Jan; 18(2):307-16. PubMed ID: 10637244
[TBL] [Abstract][Full Text] [Related]
2. Cotransplantation of HLA-identical sibling culture-expanded mesenchymal stem cells and hematopoietic stem cells in hematologic malignancy patients.
Lazarus HM; Koc ON; Devine SM; Curtin P; Maziarz RT; Holland HK; Shpall EJ; McCarthy P; Atkinson K; Cooper BW; Gerson SL; Laughlin MJ; Loberiza FR; Moseley AB; Bacigalupo A
Biol Blood Marrow Transplant; 2005 May; 11(5):389-98. PubMed ID: 15846293
[TBL] [Abstract][Full Text] [Related]
3. The use of G-CSF or GM-CSF mobilized peripheral blood progenitor cells (PBPC) alone or to augment marrow as hematologic support of single or multiple cycle high-dose chemotherapy.
Elias AD; Ayash L; Tepler I; Wheeler C; Schwartz G; Mazanet R; Schnipper L; Frei E; Antman K
J Hematother; 1993; 2(3):377-82. PubMed ID: 7522891
[TBL] [Abstract][Full Text] [Related]
4. Transplantation of enriched CD34-positive autologous marrow into breast cancer patients following high-dose chemotherapy: influence of CD34-positive peripheral-blood progenitors and growth factors on engraftment.
Shpall EJ; Jones RB; Bearman SI; Franklin WA; Archer PG; Curiel T; Bitter M; Claman HN; Stemmer SM; Purdy M
J Clin Oncol; 1994 Jan; 12(1):28-36. PubMed ID: 7505806
[TBL] [Abstract][Full Text] [Related]
5. Hematopoietic recovery of ex vivo perfusion culture expanded bone marrow and unexpanded peripheral blood progenitors after myeloablative chemotherapy.
Engelhardt M; Douville J; Behringer D; Jähne A; Smith A; Henschler R; Lange W
Bone Marrow Transplant; 2001 Feb; 27(3):249-59. PubMed ID: 11277172
[TBL] [Abstract][Full Text] [Related]
6. A feasibility study of multiple cycle therapy with melphalan, thiotepa, and paclitaxel followed by mitoxantrone, thiotepa, and paclitaxel with autologous hematopoietic cell support for metastatic breast cancer.
Hu WW; Long GD; Stockerl-Goldstein KE; Johnston LJ; Chao NJ; Negrin RS; Blume KG
Clin Cancer Res; 1999 Nov; 5(11):3411-8. PubMed ID: 10589752
[TBL] [Abstract][Full Text] [Related]
7. Double dose-intensive chemotherapy with autologous marrow and peripheral-blood progenitor-cell support for metastatic breast cancer: a feasibility study.
Ayash LJ; Elias A; Wheeler C; Reich E; Schwartz G; Mazanet R; Tepler I; Warren D; Lynch C; Gonin R
J Clin Oncol; 1994 Jan; 12(1):37-44. PubMed ID: 7505807
[TBL] [Abstract][Full Text] [Related]
8. Clinical impact of ex vivo differentiated myeloid precursors after high-dose chemotherapy and peripheral blood progenitor cell rescue.
Zimmerman TM; Lee WJ; Bender JG; Schilling M; Smith SL; Van Epps DE; Williams SF
Bone Marrow Transplant; 2000 Sep; 26(5):505-10. PubMed ID: 11019839
[TBL] [Abstract][Full Text] [Related]
9. Selection and expansion of peripheral blood CD34+ cells in autologous stem cell transplantation for breast cancer.
Williams SF; Lee WJ; Bender JG; Zimmerman T; Swinney P; Blake M; Carreon J; Schilling M; Smith S; Williams DE; Oldham F; Van Epps D
Blood; 1996 Mar; 87(5):1687-91. PubMed ID: 8634412
[TBL] [Abstract][Full Text] [Related]
10. Very large amounts of peripheral blood progenitor cells eliminate severe thrombocytopenia after high-dose melphalan in advanced breast cancer patients.
Benedetti G; Patoia L; Giglietti A; Alessio M; Pelicci P; Grignani F
Bone Marrow Transplant; 1999 Nov; 24(9):971-9. PubMed ID: 10556956
[TBL] [Abstract][Full Text] [Related]
11. Culture conditions affect the ability of ex vivo expanded peripheral blood progenitor cells to accelerate hematopoietic recovery.
Paquette RL; Dergham ST; Karpf E; Wang HJ; Slamon DJ; Souza L; Glaspy JA
Exp Hematol; 2002 Apr; 30(4):374-80. PubMed ID: 11937274
[TBL] [Abstract][Full Text] [Related]
12. Use of granulocyte colony-stimulating factor after high-dose chemotherapy and autologous peripheral blood stem cell transplantation: what is the optimal timing?
Ener RA; Meglathery SB; Cuhaci B; Topolsky D; Styler MJ; Crilley P; Brodsky I; Kahn SB; King RS
Am J Clin Oncol; 2001 Feb; 24(1):19-25. PubMed ID: 11232944
[TBL] [Abstract][Full Text] [Related]
13. CD34+ cell dose requirements for rapid engraftment in a sequential high-dose chemotherapy regimen of paclitaxel, melphalan, and cyclophosphamide, thiotepa, and carboplatin (CTCb) with PBPC support in metastatic breast cancer.
Papadopoulos KP; Ayello J; Reiss RF; Troxel A; Kaufman E; Vahdat LT; Antman KH; Hesdorffer CS
J Hematother Stem Cell Res; 1999 Aug; 8(4):357-63. PubMed ID: 10634173
[TBL] [Abstract][Full Text] [Related]
14. Optimal timing for collections of blood progenitor cells following induction chemotherapy and granulocyte-macrophage colony-stimulating factor for autologous transplantation in advanced breast cancer.
Ho AD; Glück S; Germond C; Sinoff C; Dietz G; Maruyama M; Corringham RE
Leukemia; 1993 Nov; 7(11):1738-46. PubMed ID: 7901454
[TBL] [Abstract][Full Text] [Related]
15. Thrombocytopenia after high-dose chemotherapy and autologous stem cell transplantation: an unresolved problem and possible approaches to resolve it.
Hassan HT; Zander AR
J Hematother; 1996 Aug; 5(4):407-14. PubMed ID: 8877716
[TBL] [Abstract][Full Text] [Related]
16. The additive effect of peripheral blood stem cells, harvested with low-dose cyclophosphamide, to autologous bone marrow reinfusion on hematopoietic reconstitution after ablative chemotherapy in breast cancer patients with localized disease.
de Graaf H; Mulder NH; Willemse PH; van der Graaf WT; Sleijfer DT; Zijlstra JG; Elias M; Sibinga CT; Vellenga E; de Vries EG
Anticancer Res; 1995; 15(6B):2851-6. PubMed ID: 8669878
[TBL] [Abstract][Full Text] [Related]
17. Application of whole blood and peripheral blood progenitor cells (PBPC) and new strategies for rescue after intensive cyclic chemotherapy in high-risk breast cancer.
Filip S; Bláha M; Odrázka K; Mericka P; Vávrová J
J Hematother Stem Cell Res; 2000 Feb; 9(1):31-8. PubMed ID: 10738969
[TBL] [Abstract][Full Text] [Related]
18. G-CSF primed peripheral blood progenitor cells in autologous bone marrow transplantation: parameters affecting bone marrow engraftment.
Bolwell BJ; Fishleder A; Andresen SW; Lichtin AE; Koo A; Yanssens T; Burwell R; Baucco P; Green R
Bone Marrow Transplant; 1993 Dec; 12(6):609-14. PubMed ID: 7511016
[TBL] [Abstract][Full Text] [Related]
19. Factors affecting hemopoietic recovery after high-dose therapy and autologous peripheral blood progenitor cell transplantation: a single center experience.
Olivieri A; Offidani M; Montanari M; Ciniero L; Cantori I; Ombrosi L; Masia CM; Centurioni R; Mancini S; Brunori M; Leoni P
Haematologica; 1998 Apr; 83(4):329-37. PubMed ID: 9592983
[TBL] [Abstract][Full Text] [Related]
20. Impact of preleukapheresis cell counts on collection results and correlation of progenitor-cell dose with engraftment after high-dose chemotherapy in patients with germ cell cancer.
Schwella N; Beyer J; Schwaner I; Heuft HG; Rick O; Huhn D; Serke S; Siegert W
J Clin Oncol; 1996 Apr; 14(4):1114-21. PubMed ID: 8648365
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]